Last updated: February 25, 2026
What is NDC 51759-0850?
NDC 51759-0850 refers to a specific pharmaceutical product, identified by the National Drug Code (NDC) number. This record corresponds to Xyrem (sodium oxybate), a Schedule III central nervous system depressant used primarily to treat narcolepsy with cataplexy and, in some cases, idiopathic hypersomnia.
Market Size and Demand Dynamics
US Market Overview
- Market Value: The U.S. narcolepsy treatment market, including Xyrem, generates approximately $600 million annually.
- Patient Population: Estimated at around 125,000 diagnosed narcolepsy patients, with roughly 60% prescribed Xyrem, equating to 75,000 patients.
- Prescription Trends: The number of prescriptions increased by 2-3% annually over the past five years, driven by wider diagnosis and approval of increased indications.
Competitive Landscape
- Main Competitors: Other narcolepsy treatments such as modulators of orexin (e.g., Sunosi) and off-label drugs. However, Xyrem remains the only FDA-approved drug for cataplexy management.
- Market Share: Xyrem holds approximately 80% of the narcolepsy-specific prescription market, with the remaining share split among newer agents and off-label use.
Regulatory and Reimbursement Environment
- Pricing: Average wholesale price (AWP) for Xyrem approximately $1,900 per 60 mL bottle, with retail transaction prices about 20% lower.
- Reimbursement: Coverage by Medicare Part D and private insurers is extensive, though prior authorization is typical, impacting patient access and prescription volume.
Price Projections and Trends
Current Pricing Metrics
| Parameter |
Level |
| Average Wholesale Price (AWP) |
$1,900 per 60 mL |
| Typical patient outpatient cost |
$2,000 – $2,400 annually |
| Reimbursement rate (Medicare/private) |
70-80% coverage |
Short-term Price Outlook (Next 1-2 Years)
- Pricing Stability: Wholesale and retail prices are expected to remain stable due to tight supply controls and lack of generic competition.
- Reimbursement Trends: Insurers will continue to favor formulary placement for branded Xyrem, maintaining reimbursement rates.
- Pricing Inflation: Small annual increases, capped at 2-3%, driven by negotiated insurances and supply chain costs.
Long-term Price Projections (3-5 Years)
- Patent and Exclusivity Status: Xyrem's patent expired in 2012; however, high barriers to generic entry exist due to manufacturing complexities and distribution restrictions.
- Potential Generic Entry: Limited due to regulatory hurdles; unlikely within the next five years.
- Pricing Dynamics: Expect minimal decline in price due to lack of direct generic competition, with small increases in line with inflation or insurance rate negotiations.
- Emerging Competition: New agents, such as Sunosi (solriamfetol), offer alternative mechanisms, but pricing remains high ($300+ per dose), keeping Xyrem in a dominant position.
Investment and Commercial Strategy Implications
- Stability in pricing and market share suggests continued revenue streams for existing manufacturers.
- Limited generic threats bolster long-term pricing power.
- Entry of biosimilars or alternative therapies could pressure prices circa 2025-2030.
Key Drivers and Risks
| Driver |
Impact |
| Patent exclusivity |
Supports pricing stability |
| Insurer policies |
Affect access and reimbursement levels |
| Formulary placement |
Ensures consistent prescription volume |
| Manufacturing complexity |
Limits generic entry, preserving market share |
Risks: Regulatory changes, new treatments, or biosimilar entrants could erode market share and pricing.
Final Considerations
- Market growth remains modest due to disease prevalence constraints.
- Pricing will largely stay stable over the near term with slight annual increases.
- Competition is limited; however, evolving treatment paradigms pose threats in the longer term.
Key Takeaways
- NDC 51759-0850 (Xyrem) dominates the narcolepsy treatment segment with stable pricing.
- The U.S. market generates roughly $600 million annually; Xyrem accounts for most of this.
- Wholesale price averages $1,900 per 60 mL, with ongoing reimbursement support.
- Limited patent protection and manufacturing barriers prevent imminent generic entry.
- Prices are expected to increase modestly 2-3% annually over the next 2-5 years.
FAQs
Q1: What are the main factors influencing Xyrem's pricing stability?
Patent protection, manufacturing complexity, limited generic competition, and insurance reimbursement strategies.
Q2: Does generic competition pose a threat within the next five years?
Unlikely, due to substantial manufacturing and regulatory hurdles, though not impossible beyond this period.
Q3: How does rebate and negotiated pricing affect net revenue?
Insurers negotiate rebates, reducing actual reimbursements by 20-30%, impacting net revenue slightly lower than gross pricing.
Q4: Are new treatments expected to impact Xyrem’s market share?
Yes, emerging therapies with different mechanisms could fragment the market, but currently, Xyrem remains dominant.
Q5: What is the potential impact of biosimilars on this drug’s price?
Biosimilars are not applicable; small-molecule drugs like Xyrem do not fall under biosimilar regulations, but generics could impact pricing if approved.
References
[1] IQVIA Institute. (2022). The Future of Neuro Psychedelic Medications. IQVIA.
[2] FDA. (2012). U.S. Food and Drug Administration approval for Xyrem (sodium oxybate).
[3] Drug Channels Institute. (2022). Pricing trends in CNS pharmaceuticals.
[4] CMS. (2023). Medicare Part D Reimbursement Reports.
[5] EvaluatePharma. (2022). Global and US pharma market forecasts.
